Related Experiment Video
Updated: Aug 5, 2026

Immunometabolic Circuits in Infection for Advancing Host Directed Therapies
Published on: September 13, 2024
Beyond the parasite: reframing cutaneous leishmaniasis as a host-microbiome-vector ecosystem
Marie Andrea Laetitia Huët1, Archana Bhaw-Luximon1
1Biomaterials, Drug Delivery and Nanotechnology Unit, Centre for Biomedical and Biomaterials Research, University of Mauritius, Réduit, Mauritius.
Abstract:
Disease outcomes of cutaneous leishmaniasis (CL) result from dynamic interactions between host immunity, Leishmania parasites and the host-sandfly microbiomes. Current treatments focus on parasite elimination but are limited by toxicity, drug resistance, side effects and poor wound healing. These challenges highlight the need for multi-targeted interventions by transforming CL treatment from a single-infection model to an integrated host-microbe-parasite model. This review features advances in host-microbe-parasite-vector-based strategies for CL treatment, including emerging engineering and synthetic biology approaches. We also discuss the growing role of computational and artificial intelligence (AI)-driven frameworks in guiding the design of novel therapeutics and enhancing the efficacy of existing treatments. Climate change through rising temperatures, altered precipitation, and extended suitable habitats, is likely to increase the risk and geographic range of CL in many parts of the world. By integrating these engineering platforms with AI-guided approaches, this review outlines a systems-level strategy for developing next-generation therapies aimed at reducing the global burden of CL.
Insights
Cutaneous leishmaniasis (CL) treatments need new strategies beyond parasite elimination. Integrating host, microbe, and parasite interactions with AI offers a path to advanced CL therapies.
Area of Science:
- Parasitology
- Immunology
- Microbiology
- Synthetic Biology
- Artificial Intelligence
Background:
- Cutaneous leishmaniasis (CL) disease outcomes arise from complex interactions between host immunity, Leishmania parasites, and sandfly microbiomes.
- Current CL treatments targeting parasite elimination face limitations including toxicity, drug resistance, side effects, and poor wound healing.
- A shift towards an integrated host-microbe-parasite model is necessary for developing more effective CL interventions.
Purpose of the Study:
- To review advancements in host-microbe-parasite-vector-based strategies for CL treatment.
- To explore the role of engineering, synthetic biology, and AI in developing novel CL therapeutics.
- To outline a systems-level strategy for next-generation CL therapies considering climate change impacts.
Main Methods:
- Review of current literature on host-microbe-parasite-vector interactions in CL.
- Analysis of emerging engineering and synthetic biology approaches for CL treatment.
- Discussion of computational and AI-driven frameworks for therapeutic design and efficacy enhancement.
Main Results:
- Emerging host-microbe-parasite-vector-based strategies show promise for CL treatment.
- Engineering and synthetic biology platforms, guided by AI, can enhance therapeutic development.
- Climate change is predicted to expand the geographic range and increase the risk of CL.
Conclusions:
- An integrated, systems-level approach combining engineering platforms and AI is crucial for developing next-generation CL therapies.
- Future strategies must address the multifaceted nature of CL, including host immunity, parasite, and microbiome dynamics.
- Reducing the global burden of CL requires innovative treatments that overcome current therapeutic limitations and adapt to environmental changes.
Related Concept Videos
Leishmaniasis
Microbial Interactions: Parasitism
Antiprotozoal Agents
Malaria
Amebiasis
Colonisation of Pathogens

